Actively Recruiting
Developing Outpatient Teclistamab Treatment for Adults With Relapsed or Refractory Multiple Myeloma and Assessing Caregiver Impact
Led by University Health Network, Toronto · Updated on 2025-12-10
15
Participants Needed
1
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring a new process for giving the antibody therapy teclistamab to adults with relapsed or refractory multiple myeloma in an outpatient setting. The study also aims to understand the burden on caregivers of patients receiving this outpatient treatment. This phase 4 pilot study focuses on developing safe and practical outpatient dosing methods for teclistamab, an approved treatment for patients who have tried multiple prior therapies and experienced disease progression. Participants will receive teclistamab with step-up dosing following product guidelines at different centers, including Princess Margaret Cancer Centre and Southlake Regional Cancer Centre. Some groups will receive an added dose of tocilizumab before the first step-up dose. Caregivers of patients in all treatment groups will complete questionnaires to assess how the outpatient treatment affects their quality of life and caregiving responsibilities. During the study, researchers will monitor hospital visits and treatment-related side effects for one year. Caregivers will report their quality of life using specific questionnaires over the same period. Participants will undergo regular assessments, including laboratory tests and vital sign monitoring. The study will also track toxicities and disease progression while collecting data on the outpatient dosing process and caregiver impact.
CONDITIONS
Brief Title
Plan Development for Giving Teclistamab in the Outpatient Setting
Research Team
C
Christine Chen, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here